Back to Trials
NCT07402876PHASE3Recruiting

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc.

Start Date

2/1/2026

Completion Date

12/1/2026

Summary

A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma

Eligibility Criteria

Age Range: 21 years to No maximum

Inclusion Criteria: 1. 21 years old or older; of any gender 2. Biopsy proven primary vitreoretinal lymphoma 3. Presence of lymphomatous vitreous cells at the Screening Visit and/or any eye that has been vitrectomized to confirm the diagnosis of primary vitreoretinal lymphoma 4. Willingness to participate in the clinical trial as evidenced by signing of an informed consent Exclusion Criteria: 1. Known allergy or hypersensitivity to methotrexate 2. Planned eye surgery during the clinical trial 3. Women of childbearing potential who are pregnant or lactating 4. Pre-existing ocular or non-ocular conditions or diseases that, in the opinion of the investigator, could interfere with the conduct or interpretation of the clinical trial 5. Use of systemic methotrexate within one week prior to treatment

Interventions

DRUG

ICM ADX-2191 injection

DRUG

Monthly ADX-2191 injection

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Primary Vitreoretinal Lymphoma

Locations

Bascom Palmer Eye Institute

Miami, Florida 33101

United States